United Therapeutics Corp

9 de set. de 2026, 19:36 UTC

United Therapeutics Corp shares are higher today, reaching a peak return. This movement occurs amid rising crude oil prices and inflation concerns.

8 de set. de 2026, 22:36 UTC

United Therapeutics Corp shares declined in after-market trading, following CEO Martine Rothblatt's sale of 9,500 shares valued at $4.65 million.

3 de set. de 2026, 19:56 UTC

United Therapeutics Corp's stock is trading lower, pressured despite FDA acceptance of its new drug application, reaching a 52-week low of $375.61.

2 de set. de 2026, 20:02 UTC

United Therapeutics Corp shares are declining amid concerns over insider selling by CEO Martine Rothblatt, despite positive FDA news on Tyvaso.

1 de set. de 2026, 20:08 UTC

United Therapeutics Corp shares are higher, supported by the Biotechnology sector's advance and upcoming investor conferences aimed at boosting market visibility.

31 de ago. de 2026, 22:01 UTC

The FDA accepted United Therapeutics' New Drug Application for ralinepag, aimed at treating pulmonary arterial hypertension, boosting shares modestly higher in after-market hours.

28 de ago. de 2026, 21:02 UTC

United Therapeutics shares are higher in after-market trading, recovering from a brief low earlier. Broader inflation discussions continue, with no specific company news identified.

27 de ago. de 2026, 20:01 UTC

United Therapeutics shares are trading higher as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42. The stock remains above its 20-day moving average.

26 de ago. de 2026, 19:46 UTC

United Therapeutics shares are lower as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42, raising potential supply concerns.

25 de ago. de 2026, 23:26 UTC

United Therapeutics Corp. shares are trading roughly flat in after-market hours, reflecting routine performance and remaining near the middle of their one-month trading range.

24 de ago. de 2026, 21:01 UTC

United Therapeutics shares lower in after-market hours following FDA acceptance of ralinepag's New Drug Application for pulmonary arterial hypertension.

21 de ago. de 2026, 19:46 UTC

United Therapeutics Corp shares are lower amid rising U.S. Treasury yields, which have heightened concerns about inflation and government debt levels.

20 de ago. de 2026, 23:16 UTC

Shares of United Therapeutics Corp are trading higher in after-market hours, despite routine fluctuations and a decrease from an earlier high.

19 de ago. de 2026, 22:02 UTC

United Therapeutics Corp. shares declined in after-market trading, reversing gains from the previous three sessions. No specific news was identified to explain the drop.

18 de ago. de 2026, 19:11 UTC

United Therapeutics shares are higher, supported by insider activity and full enrollment in the TETON-PPF study evaluating Tyvaso for pulmonary fibrosis.

17 de ago. de 2026, 19:46 UTC

United Therapeutics Corp completed enrollment in its Phase 3 TETON-PPF study for Tyvaso, and shares are advancing during Monday's session, despite a pullback earlier.

13 de ago. de 2026, 19:51 UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

12 de ago. de 2026, 23:01 UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

11 de ago. de 2026, 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

10 de ago. de 2026, 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

7 de ago. de 2026, 19:51 UTC

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6 de ago. de 2026, 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 de ago. de 2026, 20:02 UTC

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 de ago. de 2026, 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 de ago. de 2026, 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 de jul. de 2026, 14:36 UTC

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 de jul. de 2026, 20:51 UTC

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 de jul. de 2026, 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 de jul. de 2026, 16:36 UTC

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 de jul. de 2026, 19:41 UTC

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.